Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)

PURPOSE: Treatment options are limited for patients with recurrent and/or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC); mortality rates exceed 70% in patients with distant metastases. Here, we present the first interim analysis of the R/M cSCC cohort from the 2-cohort—locally advanced a...

Descripción completa

Detalles Bibliográficos
Autores principales: Grob, Jean-Jacques, Gonzalez, Rene, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F., Hughes, Brett G. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460151/
https://www.ncbi.nlm.nih.gov/pubmed/32673170
http://dx.doi.org/10.1200/JCO.19.03054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460151/
https://www.ncbi.nlm.nih.gov/pubmed/32673170
http://dx.doi.org/10.1200/JCO.19.03054

Ejemplares similares